Abbott Laboratories Corporation

Abbvie Inc.

Unity Biotechnology, Inc.

Autobahn Therapeutics, Inc.

Liverpool School of Tropical Medicine

Argusina Bioscience Inc.

Drugs for Neglected Diseases Initiative

Thomas W Von Geldern

Steven Armen Boyd

Martin Winn

Andrew Stewart Tasker

Bryan K Sorensen

Hwan-soo Jae

Jeffrey A Kester

Charles W Hutchins

Kenneth J Henry

Gang Liu

Steven J Wittenberger

Steven A King

Bradley J Backes

Bruce G Szczepankiewicz

Fatima Z Basha

Bing Chen

Dale J Kempf

Biswanath De

John F DeBernardis

Zhonghua Pei

Saul H Rosenberg

Anthony K Fung

Daniel Joseph Kerkman

Kennan C Marsh

Xiaofeng Li

Diane M Yamamoto

Thomas M Zydowsky

Kazumi Shiosaki

Anthony Ralph Haight

David M Barnes

Kent D Stewart

Kenton L Longenecker

Yufeng Hong

Hong Yong

Andrew S Judd

Mathew M Mulhern

David J Madar

Yong Wang

Maureen Ann McLaughlin

John E Hengeveld

Kanyin E Zhang

Stephen Andrew Ward

Jufang Barkalow

Jiayu Liao

Jinshyun Ruth Wu-Wong

Kenneth P Spina

Mark John Taylor

Robert J Padley

Todd J Janus

Louise Ford

Joseph Turner

Jean-Christophe Poupon

Jason Harris

William T Noonan

Baoku He

Hwan-Soo Jae

Eric Chatelain

Karen Breese

Jacob Heppell

Martine Keenan

Fatima Basha

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R, R, X, X, Y, and Yare as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Thyromimetics

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein X, X, and Rare as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X, X, Q, R, Rand n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders. 

Acylsulfonamide derivatives for treating senescence-associated diseases and disorders

This invention provides a method for enantioselective synthesis of cis-imidazolines and related structures through chiral resolution. A chiral acid is used to separate enantiomeric precursors of the cis-imidazolines from a racemic mixture by selective crystallization. Both enantiomers can be cyclized into the desired cis-imidazoline by complementary pathways. Compounds can be synthesized according to the invention with an enantiomeric excess as high as 99%. Cis-imidazolines such as Nutlin-3a prepared according to this invention may be used for treating cancer, killing senescent cells, or treating senescence-associated conditions.

Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use

The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.

Treatment of filarial diseases

The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.

Tylosin A analogs and derivatives

Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metabolic disorder. 

Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators

The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Vitamin D receptor activators and methods of making

The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Endothelin antagonists

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.

A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Growing community of inventors

Richmond, IL, United States of America

Thomas W Von Geldern